SynthesisFrontiers in psychiatry2021
Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis.
Synthesis in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Clinical Practice Guideline on the Pharmacological Management of Antipsychotic-Related Dyslipidemia.Schizophrenia bulletin · 2026Guideline
- Guideline
- Experimental pasta as an innovative approach to cholesterol reduction in patients with metabolic syndrome, with and without major psychiatric disorders: A randomized controlled trial supported byEuropean psychiatry : the journal of the Association of European Psychiatrists · 2025Trial
- Vitamin D, B9, and B12 Deficiencies as Key Drivers of Clinical Severity and Metabolic Comorbidities in Major Psychiatric Disorders.Nutrients · 2025Article
- Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis.Therapeutic advances in psychopharmacology · 2024Article
- A systematic review and meta-analysis of the effects of combined aripiprazole on glycolipid metabolism in schizophrenia.Frontiers in psychiatry · 2024Review
- Metabolomics, Lipidomics, and Antipsychotics: A Systematic Review.Biomedicines · 2023Review
- Serum brain-derived neurotrophic factor levels in patients with schizophrenia and methamphetamine addiction: correlation with Mini-Mental State Examination (MMSE).Journal of medicine and life · 2023Article
- Monocyte/HDL Cholesterol Ratios as a New Inflammatory Marker in Patients with Schizophrenia.Journal of personalized medicine · 2023Article
- Vitamin D supplementation is effective for olanzapine-induced dyslipidemia.Frontiers in pharmacology · 2023Article
- Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area.Therapeutic advances in psychopharmacology · 2023Article
- Acid sphingomyelinase/ceramide system in schizophrenia: implications for therapeutic intervention as a potential novel target.Translational psychiatry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.